Abstract
Angiogenesis is defined as a neoformation of blood vessels of capillary origin. Hematopoiesis is closely linked with angiogenesis, for they share a common ancestor, the hemangioblast. Although it is well established that growth in solid tumors is dependent on angiogenesis, its role in hematologic malignancies has not yet been clarified. In this review, the direct evidence, ie, increased microvessel density, and the indirect evidence, ie, elevated level of angiogenic factors or overexpression of messenger RNA or protein of angiogenic factors, for and against the role of angiogenesis in the development and progression of hematologic malignancies are presented.
Similar content being viewed by others
References
Risau W. Mechanisms of angiogenesis.Nature. 1997;386:671–674.
Yancopoulos GD, Davis S, Gale NW, Rudge JS, Wiegand SJ, Holash J. Vascular-specific growth factors and blood vessel formation.Nature. 2000;407:242–248.
Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases.Nature. 2000;407:249–257.
Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis.Cell. 1996;86:353–364.
Han ZC, Liu Y. Angiogenesis: state of the art.Int J Hematol. 1999;70:68–82.
Browder T, Folkman J, Pirie-Shepherd S. The hemostatic system as a regulator of angiogenesis.J Biol Chem. 2000;275:1521–1524.
Gastl G, Hermann T, Steurer M, et al. Angiogenesis as a target for tumor treatment.Oncology. 1997;54:177–184.
Folkman J. Clinical applications of research on angiogenesis.N Engl J Med. 1995;333:1757–1763.
Bussolino F, Di Renzo MF, Ziche M, et al. Hepatocyte growth factor is a potent angiogenic factor which stimulates endothelial cell motility and growth.J Cell Biol. 1992;119:629–641.
Grant DS, Kleinman HK, Goldberg ID, et al. Scatter factor induces blood vessel formation in vivo.Proc Natl Acad Sci U S A. 1993;90:1937–1941.
Leung DW, Cachianes G, Kuang WJ, Goeddel DV, Ferrara N. Vascular endothelial growth factor is a secreted angiogenic mitogen.Science. 1989;246:1306–1309.
Olofsson B, Korpelainen E, Pepper MS, et al. Vascular endothelial growth factor B (VEGF-B) binds to VEGF receptor-1 and regulates plasminogen activator activity in endothelial cells.Proc Natl Acad Sci U S A. 1998;95:11709–11714.
Cao Y, Linden P, Farnebo J, et al. Vascular endothelial growth factor C induces angiogenesis in vivo.Proc Natl Acad Sci U S A. 1998;95:14389–14394.
Achen MG, Jeltsch M, Kukk E, et al. Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4).Proc Natl Acad Sci U S A. 1998;95:548–553.
Cameliet P. Mechanisms of angiogenesis and arteriogenesis.Nat Med. 2000;6:389–395.
Nelson NJ. Inhibitors of angiogenesis enter phase III testing.J Natl Cancer Inst. 1998;90:960–963.
Asahara T, Murohara T, Sullivan A, et al. Isolation of putative progenitor endothelial cells for angiogenesis.Science. 1997;275:964–967.
Choi K, Kennedy M, Kazarov A, Papadimitriou JC, Keller G. A common precursor for hematopoietic and endothelial cells.Development. 1998;125:725–732.
Choi K. Hemangioblast development and regulation.Biochem Cell Biol. 1998;76:947–956.
Asahara T, Masuda H, Takahashi T, et al. Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogene-sis in physiological and pathological neovascularization.Circ Res. 1999;85:221–228.
Asahara T, Takahashi T, Masuda H, et al. VEGF contributes to postnatal neovascularization by mobilizing bone marrow-derived endothelial progenitor cells.EMBO J. 1999;18:3964–3972.
Peichev M, Naiyer AJ, Pereira D, et al. Expression of VEGF-2 and AC133 by circulating human CD34+ cells identifies a population of functional endothelial precursors.Blood. 2000;95:952–958.
Lin Y, Weisdorf DJ, Solovey A, Hebbel RP. Origins of circulating endothelial cells outgrowth from blood.J Clin Invest. 2000;105:71–77.
Shi Q, Rafii S, Wu MH, et al. Evidence for circulating bone marrow-derived endothelial cells.Blood. 1998;92:362–367.
Schuh AC, Faloon P, Hu QL, Bhimani M, Choi K. In vitro hemato-poietic and endothelial potential of flk-1 (-/-) embryonic stem cells and embryos.Proc Natl Acad Sci U S A. 1999;96:2159–2164.
Fina L, Molgaard HV, Robertson D, et al. Expression of the CD34 gene in vascular endothelial cells.Blood. 1990;75:2417–2426.
Ziegler BL, Valtieri M, Almeida Porada G, et al. KDR receptor: a key marker defining hematopoietic stem cells.Science. 1999;285:1553–1558.
Ito A, Nomura S, Hirota S, Suda J, Suda T, Kitamura Y. Enhanced expression of CD34 messenger RNA by developing endothelial cells of mice.Lab Invest. 1995;72:532–538.
Young PE, Baumhueter S, Lasky LA. The sialomucin CD34 is expressed on hematopoietic cells and blood vessels during murine development.Blood. 1995;85:96–105.
Shalaby F, Rossant J, Yamaguchi TP, et al. Failure of blood island formation and vasculogenesis in FLK-1 deficient mice.Nature. 1995;376:62–66.
Shalaby F, Ho J, Stanford WL, et al. A requirement for Flk-1 in primitive and definitive hematopoiesis and vasculogenesis.Cell. 1997;89:981–990.
Fong GH, Rossant J, Gertsenstein M, Brietman ML. Role of the FLT-1 receptor kinase in regulating the assembly of vascular endothelium.Nature. 1995;376:66–70.
Sato TN, Tozawa Y, Deutsch U, et al. Distinct roles of the receptor tyrosine kinases Tie-1 and Tie-2 in blood vessel formation.Nature. 1995;376:70–74.
Rafii S, Mohle R, Shapiro F, Frey BM, Moore MAS. Regulation of hematopoiesis by microvascular endothelium.Leuk Lymphoma. 1997;27:375–386.
Imai K, Kobayashi M, Wang J, et al. Selective transendothelial migration of hematopoietic progenitor cells: a role in homing of progenitor cells.Blood. 1999;93:149–156.
Solanilla A, Grosset C, Lemercier C, et al. Expression of Flt-ligand by the endothelial cell.Leukemia. 2000;14:153–162.
Bikfalvi A, Han ZC. Angiogenic factors are hematopoietic growth factors and vice versa.Leukemia. 1994;8:523–529.
Ribatti D, Presta M, Vacca A, et al. Human erythropoietin induces a pro-angiogenic phenotype in cultured endothelial cells and stimulates neovascularization in vivo.Blood. 1999;93:2627–2636.
Tordjman R, Delaire S, Plouet J, et al. Erythroblasts are a source of angiogenic factors.Blood. 2001;97:1968–1974.
Pelletier L, Regnard J, Fellmann D, Charbord P. An in vitro model for the study of human bone marrow angiogenesis: role of hemato-poietic cytokines.Lab Invest. 2000;80:501–511.
Broxmeyer HE, Cooper S, Li ZH, et al. Myeloid progenitor cell regulatory effects of vascular endothelial cell growth factor.Int J Hematol. 1995;62:203–215.
Bautz F, Rafii S, Kanz L, Möhle R. Expression and secretion of vascular endothelial growth factor-A by cytokine-stimulated hemato-poietic progenitor cells: Possible role in the hematopoietic microenvironment.Exp Hematol. 2000;28:700–706.
Takakura N, Watanabe T, Suenobu S, et al. A role for hematopoietic stem cells in promoting angiogenesis.Cell. 2000;102:199–209.
Hamada K, Oike Y, Takakura N, et al. VEGF-C signaling pathways through VEGFR-2 and VEGFR-3 in vasculoangiogenesis and hematopoiesis.Blood. 2000;96:3793–3800.
Zhang W, Stoica G, Tasca SI, Kelly KA, Meininger CJ. Modulation of tumor angiogenesis by stem cell factor.Cancer Res. 2000;60:6757–6762.
Brizzi MF, Battaglia E, Montrucchio G, et al. Thrombopoietin stimulates endothelial cell motility and neoangiogenesis by a platelet-activating factor-dependent mechanism.Circ Res. 1999;84:785–796.
Crisa L, Cirulli V, Smith KA, Ellisman MH, Torbett BE, Salomon DR. Human cord blood progenitors sustain thymic T-cell development and a novel form of angiogenesis.Blood. 2000;94:3928–3940.
Katoh O, Tauchi H, Kawaishi K, Kimura A, Satow Y. Expression of the vascular endothelial growth factor (VEGF) receptor gene, KDR, in hematopoietic cells and inhibitory effect of VEGF on apoptotic cell death caused by ionizing radiation.Cancer Res. 1995;55:5687–5692.
Ratajczak MZ, Ratajczak J, Machalinski B, et al. Role of vascular endothelial growth factor (VEGF) and placenta-derived growth factor (PIGF) in regulating human haemopoietic cell growth.Br J Haematol. 1998;103:969–979.
Hattori K, Dias S, Heissig B, et al. Vascular endothelial growth factor and angiopoietin-1 stimulate postnatal hematopoiesis by recruitment of vasculogenic and hematopoietic stem cells.J Exp Med. 2001;193:1005–1014.
Wartiovaara U, Salven P, Mikkola H, et al. Peripheral blood platelets express VEGF-C and VEGF which are released during platelet activation.Thromb Haemost. 1998;80:171–175.
Mohle R, Green D, Moore MAS, Nachman RL, Rafii S. Constitutive production and thrombin-induced release of vascular endothe-lial growth factor by human megakaryocytes and platelets.Proc Natl Acad Sci U S A. 1997;94:663–668.
Villars F, Bordenave L, Bareille R, Amedee J. Effect of human endothelial cells on human bone marrow stromal cell phenotype: role of VEGF?J Cell Biochem. 2000;79:672–685.
Ikehara S. Role of hepatocyte growth factor in hemopoiesis.Leuk Lymphoma. 1996;23:297–303.
Nishino T, Hisha H, Nishino N, Adachi M, Ikehara S. Hepatocyte growth factor as a hematopoietic regulator.Blood. 1995;85:3093–3100.
Takai K, Hara J, Matsumoto K, et al. Hepatocyte growth factor is constitutively produced by human bone marrow stromal cells and indirectly promotes hematopoiesis.Blood. 1997;89:1560–1565.
DeCarvalho S. In vitro angiogenic activity of RNA from leukemic lymphocytes.Angiology. 1978;29:497–505.
Nguyen M, Watanabe H, Budson AE, Richie JP, Hayes DF, Folk-man J. Elevated levels of an angiogenic peptide, basic fibroblast growth factor, in the urine of patients with a wide spectrum of cancers.J Natl Cancer Inst. 1994;86:356–361.
Perez-Atayde AR, Sallan SE, Tedrow U, Connors S, Allred E, Folkman J. Spectrum of tumor angiogenesis in the bone marrow of children with acute lymphoblastic leukemia.Am J Pathol. 1997;150:815–821.
Schneider P, Jerome MV, Soria PC, Vannier JP. The role of angio-genesis in leukemia proliferation.Am J Pathol. 1999;155:1007–1009.
Vacca A, Ribatti D, Iurlaro M, et al. Human lymphoblastoid cells produce extracellular matrix-degrading enzymes and induce endothelial cell proliferation, migration, morphogenesis, and angiogenesis.Int J Clin Lab Res. 1998;28:55–68.
Bellamy WT, Richter L, Frutiger Y, Grogan TM. Expression of vascular endothelial growth factor and its receptors in hematopoietic malignancies.Cancer Res. 1999;59:728–733.
Fiedler W, Graeven U, Ergun S, et al. Vascular endothelial growth factor, a possible paracrine growth factor in human acute myeloid leukemia.Blood. 1997;89:1870–1875.
Fiedler W, Graeven U, Ergun S, et al. Expression of FLT4 and its ligand VEGF-C in acute myeloid leukemia.Leukemia. 1997;11:1234–1237.
Hayashibara T, Fujimoto T, Miyanishi T, et al. Vascular endothelial growth factor at high plasma levels is associated with extranodal involvement in adult T cell leukemia patients.Leukemia. 1999;13:1634–1635.
Aguayo A, Estev E, Kantarjian H, et al. Cellular vascular endothe-lial growth factor is a predictor of outcome in patients with acute myeloid leukemia.Blood. 1999;94:3717–3721.
Hussong JW, Rodgers GM, Shami PJ. Evidence of increased angio-genesis in patients with acute myeloid leukemia.Blood. 2000;95:309–313.
Padro T, Ruiz S, Bieker R, et al. Increased angiogenesis in the bone marrow of patients with acute myeloid leukemia.Blood. 2000;95:2637–2644.
Aguayo A, Kantarjian H, Manshouri T, et al. Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes.Blood. 2000;96:2240–2245.
Dias S, Hattori K, Zhu Z, et al. Autocrine stimulation of VEGF-2 activates human leukemic cell growth and migration.J Clin Invest. 2000;106:511–521.
Fusetti L, Pruneri G, Gobbi A, et al. Human myeloid and lymphoid malignancies in the non-obese diabetic/severe combined immunodeficiency mouse model: frequency of apoptotic cells in solid tumors and efficiency and speed of engraftment correlate with vascular endothelial growth factor production.Cancer Res. 2000;60:2527–2534.
Foss B, Mentzoni L, Bruserud O. Effects of vascular endothelial growth factor on acute myelogenous leukemia blasts.J Hematother Stem Cell Res. 2001;10:81–93.
Molica S, Vitelli G, Levato D, Gandolfo GM, Liso V. Increased serum levels of vascular endothelial growth factor predict risk of progression in early B-cell chronic lymphocytic leukaemia.Br J Haematol. 1999;107:605–610.
Chen H, Treweeke AT, West DC, et al. In vitro and in vivo production of vascular endothelial growth factor by chronic lymphocytic leukemia cells.Blood. 2000;96:3181–3187.
Kini AR, Kay NE, Peterson LC. Increased bone marrow angiogen-esis in B cell chronic lymphocytic leukemia.Leukemia. 2000;14:1414–1418.
Aguayo A, O’Brien S, Keating M, et al. Clinical relevance of intra-cellular vascular endothelial growth factor levels in B-cell chronic lymphocytic leukemia.Blood. 2000;96:768–770.
Ferrajoli A, Manshouri T, Estrov Z, et al. High levels of vascular endothelial growth factor receptor-2 correlate with shortened survival in chronic lymphocytic leukemia.Clin Cancer Res. 2001;7:795–799.
Aguayo A, Manshouri T, O’Brien S, et al. Clinical relevance of Flt1 and Tie1 angiogenesis receptors expression in B-cell chronic lym-phocytic leukemia (CLL).Leuk Res. 2001;25:279–285.
Krejci P, Dvorak D, Krahulcova E, et al. FGF-2 abnormalities in B cell chronic lymphocytic and chronic myeloid leukemias.Leukemia. 2001;15:228–237.
Nakamura S, Gohda E, Matsuo Y, Yamamoto I, Minowada J. Significant amount of hepatocyte growth factor detected in blood and bone marrow plasma of leukemia patients.Br J Haematol. 1994;87:640–642.
Hino M, Inaba M, Goto H, et al. Hepatocyte growth factor levels in bone marrow plasma of patients with leukaemia and its gene expression in leukaemic blast cells.Br J Cancer. 1996;73:119–123.
Hjorth-Hansen H, Seidel C, Lamvik J, Borset M, Sundan A, Waage A. Elevated serum concentrations of hepatocyte growth factor in acute myelocytic leukemia.Eur J Haematol. 1999;62:129–134.
Pons E, Uphoff CC, Drexler HG. Expression of hepatocyte growth factor and its receptor c-met in human leukemia-lymphoma cell lines.Leuk Res. 1998;22:797–804.
Weimar IS, Voermans C, Bourhis JH, et al. Hepatocyte growth factor/scatter factor (HGF/SF) affects proliferation and migration of myeloid leukemic cells.Leukemia. 1998;12:1195–1203.
Jucker M, Gunther A, Gradl G, et al. The Met/hepatocyte growth factor receptor (HGFR) gene is overexpressed in some cases of human leukemia and lymphoma.Leuk Res. 1994;18:7–16.
Katoh O, Takahashi T, Oguri T, Kuramoto K, Watanabe H. Vascular endothelial growth factor inhibits apoptotic death in hemato-poietic cells after exposure to chemotherapeutic drugs by inducing MCL1 acting as an antiapoptotic factor.Cancer Res. 1998;58:5565–5569.
Massova I, Khotra LP, Fridman R, Mahashery S. Matrix metallo-proteinases: structures, evolution, and diversification.FASEB J. 1998;12:1075–1095.
Morgunova E, Tuuttila A, Bergmann U, et al. Structure of human pro-matrix metalloproteinase-2: activation mechanism revealed.Science. 1999;284:1667–1670.
Stetler-Stevenson WG, Hewitt R, Corcoran M. Matrix metallopro-teinases and tumor invasion: from correlation and causality to the clinic.Semin Cancer Biol. 1996;7:47–154.
Janowska-Wieczorek A, Marquez LA, Matsuzaki A, et al. Expression of matrix metalloproteinases (MMP-2 and MMP-9) and tissue inhibitors of metalloproteinases (TIMP-1 and -2) in acute myel-ogenous leukemia blasts: comparison with normal bone marrow cells.Br J Haematol. 1999;105:402–411.
Lundberg LG, Lerner R, Sundelin P, Rogers R, Folman J, Palmblad J. Bone marrow in polycythemia vera, chronic myelocytic leukemia and myelofibrosis has an increased vascularity.Am J Pathol. 2000;157:15–19.
Mesa RA, Hanson CA, Rajkumar SV, Schroeder G, Tefferi A. Evaluation and clinical correlations of bone marrow angiogenesis in myelofibrosis with myeloid metaplasia.Blood. 2000;96:3374–3380.
Yoon SY, Teffer A, Li CY. Bone marrow stromal cell distribution of basic fibroblast growth factor in chronic myeloid disorders.Haema-tologica. 2001;86:52–57.
Pruneri G, Bertolini F, Soligo D, et al. Angiogenesis in myelodys-plastic syndromes.Br J Cancer. 1999;81:1398–1401.
Bellamy WT, Richter L, Sirjani D, et al. Vascular endothelial cell growth factor is an autocrine promoter of abnormal localized immature myeloid precursors and leukemia progenitor formation in myelodysplastic syndromes.Blood. 2001;97:1427–1434.
Gunsilius E, Duba HC, Petzer AL, et al. Evidence from a leukemia model for maintenance of vascular endothelium by bone-marrow-derived endothelial cells.Lancet. 2000;355:1688–1691.
Ribatti D, Vacca A, Nico B, et al. Bone marrow angiogenesis and mast cell density increase simultaneously with progression of human multiple myeloma.Br J Cancer. 1999;79:451–455.
Vacca A, Ribatti D, Roncall L, et al. Bone marrow angiogenesis and progression in multiple myeloma.Br J Haematol. 1994;87:503–508.
Vacca A, Ribatti D, Roncall L, Dammacco F. Angiogenesis in B cell lymphoproliferative diseases. Biological and clinical studies.Leuk Lymphoma. 1995;20:27–38.
Rajkumar SV, Fonseca R, Witzig TE, Gertz MA, Greipp PR. Bone marrow angiogenesis in patients achieving complete response after stem cell transplantation for multiple myeloma.Leukemia. 1999;13:469–472.
Laroche M, Brousset P, Ludot I, et al. Increased vascularization in myeloma.Eur J Haematol. 2001;66:89–93.
Rajkumar SV, Leong T, Roche PC, et al. Prognostic value of bone marrow angiogenesis in multiple myeloma.Clin Cancer Res. 2000;6:3111–3116.
Sezer O, Niemoller K, Eucker J, et al. Bone marrow microvessel density is a prognostic factor for survival in patients with multiple myeloma.Ann Hematol. 2000;79:574–577.
Ahn MJ, Park CK, Choi JH, et al. Clinical significance of microves-sel density in multiple myeloma patients.J Korean Med Sci. 2001;16:45–50.
Schreiber S, Ackermann J, Obermair A, et al. Multiple myeloma with deletion of chromosome 13q is characterized by increased bone marrow neovascularization.Br J Haematol. 2000;110:605–609.
Vacca A, Di Loreto M, Ribatti D, et al. Bone marrow of patients with active multiple myeloma: angiogenesis and plasma cell adhesion molecules LFA-1, VLA-4, LAM-1, and CD44.Am J Hematol. 1995;50:9–14.
Sezer O, Jakob C, Eucker J, et al. Serum levels of the angiogenic cytokines basic fibroblast growth factor (bFGF), vascular endothe-lial growth factor (VEGF) and hepatocyte growth factor (HGF) in multiple myeloma.Eur J Haematol. 2001;66:83–88.
Di Raimondo F, Azzaro MP, Palumbo GA, et al. Angiogenic factors in multiple myeloma: higher levels in bone marrow than in peripheral blood.Haematologica. 2000;85:800–805.
Seidel C, Borset M, Hjertner O, et al. High level of soluble synde-can-1 in myeloma-derived bone marrow: modulation of hepatocyte growth factor activity.Blood. 2000;96:3139–3146.
Dankbar B, Padro T, Leo R, et al. Vascular endothelial growth factor and interleukin-6 in paracrine tumor-stromal cell interactions in multiple myeloma.Blood. 2000;95:2630–2636.
Seidel C, Borset M, Turesson I, Abildgaard N, Sundan A, Waage A for the Nordic Myeloma Study Group. Elevated serum concentrations of hepatocyte growth factor in patients with multiple myeloma.Blood. 1998;91:806–812.
Borset M, Hjorth-Hansen H, Seidel C, Sundan A, Waage A. Hepa-tocyte growth factor and its receptor c-Met in multiple myeloma.Blood. 1996;88:3998–4004.
Borset M, Seidel C, Hjorth-Hansen H, Waage A, Sundan A. The role of hepatocyte growth factor and its receptor c-met in multiple myeloma and other blood malignancies.Leuk Lymphoma. 1999;32:249–256.
Vacca A, Ribatti D, Presta M, et al. Bone marrow neovasculariza-tion, plasma cell angiogenic potential, and matrix metallopro-teinase-2 secretion parallel progression of human multiple myeloma.Blood. 1999;93:3064–3073.
Yaccoby S, Barlogie B, Epstein J. Primary myeloma cells growing in SCID-hu mice: a model for studying the biology and treatment of myeloma and its manifestations.Blood. 1998;92:2908–2913.
Dominici M, Campioni D, Lanza F, et al. Angiogenesis in multiple myeloma: correlation between in vitro endothelial colonies growth (CFU-En) and clinical-biological features.Leukemia. 2001;15:171–176.
Foss HD, Araujo I, Demel G, Klotzbach H, Hummel M, Stein H. Expression of vascular endothelial growth factor in lymphomas and Castleman’s disease.J Pathol. 1997;183:44–50.
Salven P, Teerenhovi L, Joensuu H. A high pretreatment serum vascular endothelial growth factor concentration is associated with poor outcome in non-Hodgkin’s lymphoma.Blood. 1997;90:3167–3172.
Salven P, Teerenhovi L, Joensuu H. A high pretreatment serum basic fibroblast growth factor concentration is an independent predictor of poor prognosis in non-Hodgkin’s lymphoma.Blood. 1999;94:3334–3339.
Salven P, Orpana A, Teerenhovi L, Joensuu H. Simultaneous elevation in the serum concentrations of the angiogenic growth factors VEGF and bFGF is an independent predictor of poor prognosis in non-Hodgkin lymphoma: a single-institution study of 200 patients.Blood. 2000;96:3712–3718.
Bertolini F, Paolucci M, Peccatori F, et al. Angiogenic growth factors and endostatin in non-Hodgkin’s lymphoma.Br J Haematol. 1999;106:504–509.
Ribatti D, Vacca RD, Nico B, Fanelli M, Roncali L, Dammacco F. Angiogenesis spectrum in the stroma of B-cell non-Hodgkin’s lymphomas. An immunohistochemical and ultrastructural study.Eur J Haematol. 1996;56:45–53.
Weimar IS, de Jong D, Muller EJ, et al. Hepatocyte growth factor/ scatter factor promotes adhesion of lymphoma cells to extracellular matrix molecules via α4β1 and α5β1 integrins.Blood. 1997;89:990–1000.
Teofili L, Di Febo AL, Pierconti F, et al. Expression of the c-met proto-oncogene and its ligand, hepatocyte growth factor, in Hodg-kin disease.Blood. 2001;97:1063–1069.
Schaerer L, Schmid MH, Mueller B, Dummer RG, Burg G, Kempf W. Angiogenesis in cutaneous lymphoproliferative disorders: microvessel density discriminates between cutaneous B-cell lymphomas and B-cell pseudolymphomas.Am J Dermatopathol. 2000;22:140–143.
Ribatti D, Vacca A, Marzullo A, et al. Angiogenesis and mast cell density with tryptase activity increase simultaneously with pathological progression in B-cell non-Hodgkin’s lymphomas.Int J Cancer. 2000;85:171–175.
Vacca A, Ribatti D, Ruco L, et al. Angiogenesis extent and macrophage density increase simultaneously with pathological progression in B-cell non-Hodgkin’s lymphomas.Br J Cancer. 1999;79:965–970.
Bairey O, Zimra Y, Kaganovsky E, Shaklai M, Okon E, Rabizadeh E. Microvessel density in chemosensitive and chemoresistant diffuse large B-cell lymphomas.Med Oncol. 2000;17:314–318.
Vacca A, Morretti S, Ribatti D, et al. Progression of mycosis fun-goides is associated with changes in angiogenesis and expression of matrix metalloproteinases 2 and 9.Eur J Cancer. 1997;33:1685–1692.
Croix BS, Rago C, Victor V, et al. Genes expressed in human tumor endothelium.Science. 2000;289:1197–1202.
Singhal S, Mehta J, Desikan R, et al. Antitumor activity of thalidomide in refractory multiple myeloma.N Engl J Med. 1999;341:1565–1571.
Neben K, Hawighorst H, Moehler TM, et al. Clinical response to thalidomide monotherapy correlates with improvement in dynamic magnetic resonance (d-MRI) angiogenesis parameters [abstract].Blood. 1999;94:124a.
Juliusson G, Celsing F, Turesson I, Adriansson M, Malm C. Thalidomide frequently induces good partial remission and best response ever in patients with advanced myeloma and prior high dose mel-phalan and autotransplant [abstract].Blood. 1999;94:124a.
Raza S, Veksler Y, Sabir T, Li Z, Anderson L, Jagannath S. Durable response to thalidomide in relapse/refractory multiple myeloma (MM)[abstract].Blood. 2000;96:168a.
Moehler TM, Neben K, Hawighorst H, et al. Thalidomide plus CED chemotherapy as salvage therapy in poor prognosis multiple myeloma [abstract].Blood. 2000;96:290b.
Durie BGM, Stepan DE. Efficacy of low dose thalidomide (T) in multiple myeloma [abstract].Blood. 1999;94:316a.
Rajkumar SV, Fonseca R, Dispenzieri A, et al. Thalidomide in the treatment of relapsed and refractory myeloma.Mayo Clin Proc. 2000;75:897–901.
Schiller G, Vescio R, Berenson J. Thalidomide for the treatment of multiple myeloma relapsing after autologous peripheral blood progenitor cell transplant [abstract].Blood. 1999;94:317a.
Desikan R, Munshi N, Zeldis J, et al. Activity of thalidomide (THAL) in multiple myeloma (MM) confirmed in 180 patients with advanced disease [abstract].Blood. 1999;94:603a.
Weber DM, Gavino M, Delasalle K, Rankin K, Giralt S, Alexanian R. Thalidomide alone or with dexamethasone for multiple myeloma [abstract].Blood. 1999;94:604a.
Chen CI, Adesanya A, Sutton DM, Brandwein J, Stewart AK. Low-dose thalidomide in patients with advanced refractory multiple myeloma [abstract].Blood. 1999;94:308b.
Wu K, Schaafsma MR, Smit WM, Neef C, Richel DJ. Thalidomide as anti-angiogenesis treatment in patients with chemotherapy resistant multiple myeloma (MM) [abstract].Blood. 1999;94:316b.
Kneller A, Raanani P, Hardan I, et al. Therapy with thalidomide in refractory multiple myeloma patients-the revival of an old drug.Br J Haematol. 2000;108:391–393.
Coleman M, Gelfand RM, Leonard JP. Combination non-myelo-suppressive therapy (thalidomide, clarithromycin, dexamethasone) for plasma cell myeloma: a preliminary report [abstract].Blood. 1999;94:308b.
Srkalovic G, Karam MA, Mclain DA, Hussein MA. Melphalan, thalidomide and decadron (MTD) for refractory/relapsed multiple myeloma (MM) [abstract].Blood. 1999;94:314b.
Zomas A, Anagnostopoulos N, Dimopoulos MA. Successful treatment of multiple myeloma relapsing after high-dose therapy and autologous transplantation with thalidomide as a single agent.Bone Marrow Transplant. 2000;25:1319–1320.
Weber DM, Rankin K, Gavino M, Delasalle K, Alexanian R. Thal-idomide with dexamethasone for resistant multiple myeloma.Blood. 2000;96:167a.
Palumbo A, Giaccone L, Bertola A, et al. Low-dose thalidomide plus dexamethasone is an effective salvage therapy for advanced myeloma.Haematologica. 2001;86:399–403.
Yakoub-Agha I, Attal M, Dumontet C, et al. Thalidomide in patients with advanced myeloma: survival prognostic factors.Blood. 2000;96:167a.
Rajkumar SV, Hayman S, Fonseca R, et al. Thalidomide plus dex-amethasone (Thal/Dex) and thalidomide alone (Thal) as first line therapy for newly diagnosed myeloma [abstract].Blood. 2000;96:168a.
Barlogie B, Spencer T, Tricot G, et al. Long term follow up of 169 patients receiving a phase II trial of single agent thalidomide for advanced and refractory multiple myeloma (MM).Blood. 2000;96:514a.
D’Amato RJ, Loughnan MS, Flynn E, et al. Thalidomide is an inhibitor of angiogenesis.Proc Natl Acad Sci U S A. 1994;91:4082–4085.
Shima Y, Treon SP, Yoshizaki K, et al. Clinical and biological activity of thalidomide (THAL) in multiple myeloma (MM) [abstract].Blood. 1999;94:125a.
Cheng D, Kini AR, Rodriguez J, Burt RK, Peterson LC, Traynor AE. Microvascular density and cytotoxic T cell activation correlate with response to thalidomide therapy in myeloma patients [abstract].Blood. 1999;94:315a.
Haslett PAJ, Corral LG, Albert M, Kaplan G. Thalidomide costim-ulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8+ subset.J Exp Med. 1998;187:1885–1892.
Geitz H, Handt S, Zwingenberger K. Thalidomide selectively modulates the density of cell surface molecules involved in the adhesion cascade.Immunopharmacol. 1996;31:213–221.
Or R, Feferman R, Shoshan S. Thalidomide reduces vascular density in granulation tissue of subcutaneously implanted polyvinyl alcohol sponges in guinea pigs.Exp Hematol. 1998;26:217–221.
Sauer H, Gunther J, Hescheler J, Wartenberg M. Thalidomide inhibits angiogenesis in embryoid bodies by the generation of hydroxyl radicals.Am J Pathol. 2000;156:151–158.
Bauer KS, Dixon SC, Figg WD. Inhibition of angiogenesis by thalidomide requires metabolic activation, which is species-dependent.Biochem Pharmacol. 1998;55:1827–1834.
Petrucci MT, Ricciardi MR, Gregorj C, et al. Thalidomide effects on apoptosis in multiple myeloma: ex-vivo and in vitro study.Blood. 2000;96:366a.
Hideshima T, Chauhan D, Shima Y, et al. Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy.Blood. 2000;2943–2950.
Rajkumar SV, Timm M, Mesa RA, et al. Effect of thalidomide on myeloma cell apoptosis and VEGF secretion.Blood. 2000;96:364a.
Thomas DA, Aguayo A, Estey E, et al. Thalidomide as anti-angio-genesis therapy (RX) in refractory or relapsed leukemias [abstract].Blood. 1999;94:507a.
Raza A, Lisak L, Andrews C, et al. Thalidomide produces transfusion independence in patients with long-standing refractory anemias and myelodysplastic syndromes (MDS) [abstract].Blood. 1999;94:661a.
Thoma DA, Aguayo A, Giles FJ, et al. Thalidomide anti-angiogen-esis therapy (RX) in Philadelphia (Ph)-negative myeloproliferative disorders (MPD) and myelofibrosis (MF) [abstract].Blood. 1999;94:702a.
Estey E, Albitar M, Cortes J, et al. Addition of thalidomide(T) to chemotherapy did not increase remission rate in poor prognosis AML/MDS.Blood. 2000;96:323a.
Boehm T, Folkman J, Browder T, O’Reilly MS. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance.Nature. 1997;390:404–407.
Mantell DJ, Owens PE, Bundred NJ, Mawer EB, Canfield AE. 1 α,25-dihydroxyvitamin D3 inhibits angiogenesis in vitro and in vivo.Circ Res. 2000;87:214–220.
Roboz GJ, Dias S, Lam G, et al. Arsenic trioxide induces dose- and time-dependent apoptosis of endothelium and may exert an antileukemic effect via inhibition of angiogenesis.Blood. 2000;96:1525–1530.
Vacca A, Iurlaro M, Ribatti D, et al. Antiangiogenesis is produced by nontoxic doses of vinblastine.Blood. 1999;94:4143–4155.
Yao L, Pike SE, Setsuda J, et al. Effective targeting of tumor vasculature by the angiogenesis inhibitors vasostatin and interleukin-12.Blood. 2000;96:1900–1905.
Cervenak L, Morbidell L, Donati D, et al. Abolished angiogenicity and tumorigenicity of Burkitt lymphoma by interleukin-10.Blood. 2000;96:2568–2573.
Bertolini F, Fusetti L, Rabascio C, Cinieri S, Martinelli G, Pruneri G. Inhibition of angiogenesis and induction of endothelial and tumor cell apoptosis by green tea in animal models of human high-grade non-Hodgkin’s lymphoma.Leukemia. 2000;14:1477–1482.
Bertolini F, Fusetti L, Mancuso P, et al. Endostatin, an antiangiogenic drug, induces tumor stabilization after chemotherapy or anti-CD20 therapy in a NOD/SCID mouse model of human high-grade non-Hodgkin lymphoma.Blood. 2000;96:282–287.
Author information
Authors and Affiliations
Corresponding author
About this article
Cite this article
Yang, R., Han, Z.C. Angiogenesis in Hematologic Malignancies and Its Clinical Implications. Int J Hematol 75, 246–256 (2002). https://doi.org/10.1007/BF02982037
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF02982037